Abstract: Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding sequence may be retroinverted D-peptide mimetic of an L-peptide binding sequence and the transit sequence may be a D-peptide mimetic of an L-peptide transit sequence (e.g. TAT) The preferred peptide construct comprises the sequence rGffvlkGrrrrqrrkkrGy. The preferred carrier particles are liposomes.

Abstract: Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding sequence may be retroinverted D-peptide mimetic of an L-peptide binding sequence and the transit sequence may be a D-peptide mimetic of an L-peptide transit sequence (e.g. TAT) The preferred peptide construct comprises the sequence rGffvlkGrrrrqrrkkrGy. The preferred carrier particles are liposomes.

Abstract: A method of detecting and classifying mental states, comprising the steps of receiving bio-signals from one or more bio-signal detectors; generating multiple different representations of each bio-signal; determining the value of one or more features of the each bio-signal representation; and comparing the feature values to one or more than one mental state signature, each mental state signature defining reference feature values indicative of a predetermined mental state.

Abstract: The present invention relates to a sensor device and method for determining the extent of aggregation of a protein such as beta amyloid in a fluid (e.g. a bodily fluid).

Abstract: Surface profiling apparatus (10) according to one embodiment comprises three long period gratings (LPGs) (12, 14, 16) fabricated in progressive three layered (PTL) fibre (18) and embedded within a deformable carrier member (40) comprising a skeleton (42) provided between two sheets of flexible rubber skin (44, 46). The LPGs (12, 14, 16) are illuminated by three wavelength modulated, narrow bandwidth optical signals, each having a different wavelength and modulation frequency. A photodetector (26) connected to three lock-in amplifiers (28, 30, 32) measures the amplitudes of the first and second harmonic frequency components of the photodetector output signal corresponding to each LPG (12, 14, 16). Similar surface profiling apparatus (10) forms the basis for respiratory function monitoring apparatus (100) in which five LPGs are provided within each of four PTL fibres (104, 106, 108, 110) and embedded in four carrier members (40a-d) attached to a garment (114) to be worn by a subject.

Abstract: The invention provides a method of diagnosing a synucleinopathy in a patient and also a method monitoring the effectiveness of a therapeutic agent that has been administered to a patient for the purpose of treating a synucleinopathy. The method comprises analysing a non-cerebral body fluid sample taken from the patient for the presence and/or amount of a synuclein in said sample. The synuclein may be an aggregated synuclein.